ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

ImeABBVON

PoredakNo.3332

Tržišna kapitalizacija$0.00

Potpuno razrijeđena tržišna kapitalizacija$0.00

Tržišni udio%

Obujam trgovanja / tržišna kapitalizacija (24-satni)896,557.09%

Količina u optjecaju125.77024904

Maksimalna količina0

Ukupna količina125.77024904

Stopa optjecaja%

Datum izdavanja--

Cijena po kojoj je imovina prvi put izdana--

Najviša vrijednost svih vremena237.64005999136555,2026-03-05

Najniža cijena193.3720963640878,2026-04-29

Javni blockchainETH

UvodAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sektor

Društvene mreže

• Službena web-stranica
• Blokiraj pretraživač

etfindex:mc_etfindex_sourceOdricanje od odgovornosti: Podatke pruža cmc i ne smiju se smatrati investicijskim savjetom.